<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="0daee3b8-efec-4ff2-aedf-87035563373f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Azithromycin safely and effectively. See full prescribing information for Azithromycin. <br/>AZITHROMYCIN for injection, for intravenous use <br/>Initial U.S. Approval: 2009</title>
   <effectiveTime value="20250416"/>
   <setId root="d2f4907f-b952-403b-229e-cc5b8327a773"/>
   <versionNumber value="30"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="141588017" root="1.3.6.1.4.1.519.1"/>
            <name>Hospira, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="030606222" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="827731089" root="1.3.6.1.4.1.519.1"/>
                        <name>Hospira, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="862e4049-b8fa-49e1-ab82-540969f5a3c8"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20220203"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0409-0144" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Azithromycin</name>
                        <formCode code="C42957" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>AZITHROMYCIN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="500"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JTE4MNN1MD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AZITHROMYCIN MONOHYDRATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="J2KLZ20U1M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AZITHROMYCIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XF417D3PSL" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS CITRIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0409-0144-21" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43215" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-DOSE"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0409-0144-11" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C53438" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TRAY"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20090626"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065500" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20090626"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INTRAVENOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_87398fce-6108-4931-9166-7d450e1b5617">
               <id root="119c734d-f98c-4176-a3c5-9de89fb3c3fd"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="85%"/>
                           <col width="15%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Warnings and Precautions, Cardiovascular Death (<linkHtml href="#_RefS5.5">5.5</linkHtml>)</paragraph>
                                 </td>
                                 <td align="center" valign="bottom">
                                    <paragraph>11/2021</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_95d038ca-ec12-4bfb-88f6-ff97004d08b3">
               <id root="16e0619f-64b4-4189-a193-4e0b2b50a959"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Azithromycin for Injection, USP is a macrolide antibacterial drug indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below.</paragraph>
               </text>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Azithromycin is a macrolide antibacterial drug indicated for mild to moderate infections caused by designated, susceptible bacteria:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Community-acquired pneumonia in adults (<linkHtml href="#_RefID_f3308b06-81b1-4d68-8852-17dad07fb">1.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pelvic inflammatory disease (<linkHtml href="#_RefID_0d699a61-a975-403a-ba16-f98a706f2">1.2</linkHtml>)</item>
                        </list>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. (<linkHtml href="#_RefS1.3">1.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_f3308b06-81b1-4d68-8852-17dad07fb244">
                     <id root="9bb23272-0653-4314-b920-9dc5300dc48a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Community-Acquired Pneumonia </title>
                     <text>
                        <paragraph>due to <content styleCode="italics">Chlamydophila pneumoniae</content>, <content styleCode="italics">Haemophilus influenzae</content>, <content styleCode="italics">Legionella pneumophila</content>, <content styleCode="italics">Moraxella catarrhalis</content>, <content styleCode="italics">Mycoplasma pneumoniae</content>, <content styleCode="italics">Staphylococcus aureus</content>, or <content styleCode="italics">Streptococcus pneumoniae </content>in patients who require initial intravenous therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0d699a61-a975-403a-ba16-f98a706f2e05">
                     <id root="867e1906-60be-4d95-bec9-670f8f0cee17"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Pelvic Inflammatory Disease </title>
                     <text>
                        <paragraph>due to <content styleCode="italics">Chlamydia trachomatis</content>, <content styleCode="italics">Neisseria gonorrhoeae</content>, or <content styleCode="italics">Mycoplasma hominis </content>in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with Azithromycin.</paragraph>
                        <paragraph>Azithromycin for Injection, USP should be followed by azithromycin the oral route as required [<content styleCode="italics">see <linkHtml href="#ID_2246c2cd-4d47-44e1-b594-134f22aa22bd">Dosage and Administration (2)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="52e2b4eb-43df-40c4-be1a-657783957564"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_27b5f9ef-0e24-4389-b5c1-56583f4e5389">
               <id root="18ced985-5b3f-4814-a4b7-ea493c7adebd"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>[<content styleCode="italics">see <linkHtml href="#S1.3">Indications and Usage (1)</linkHtml> and <linkHtml href="#_RefID_df229571-1c41-4ddb-b6ab-9aecf3816">Clinical Pharmacology (12.3)</linkHtml>
                     </content>].</paragraph>
               </text>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Community-acquired pneumonia: 500 mg as a single daily dose by the intravenous route for at least two days. (<linkHtml href="#_RefID_2d98aeba-b3a9-4dc1-b7a9-8b2d67e03">2.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Pelvic inflammatory disease in adults: 500 mg as a single daily dose by the intravenous route for one or two days. (<linkHtml href="#_RefID_a90e2a8f-2cd4-40af-9780-bdf532f75">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_2d98aeba-b3a9-4dc1-b7a9-8b2d67e034f9">
                     <id root="d73abb12-f09c-4a28-8b98-27bca9f4f5e5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Community-Acquired Pneumonia</title>
                     <text>
                        <paragraph>The recommended dose of Azithromycin for Injection, USP for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a90e2a8f-2cd4-40af-9780-bdf532f758ee">
                     <id root="4c8ddd5d-2807-439f-8388-10f7c164beea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pelvic Inflammatory Disease</title>
                     <text>
                        <paragraph>The recommended dose of Azithromycin for Injection, USP for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2246c2cd-4d47-44e1-b594-134f22aa22bd">
                     <id root="c21c0faf-ef60-4d76-b3c4-805ca3431d86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Preparation of the Solution for Intravenous Administration</title>
                     <text>
                        <paragraph>The infusate concentration and rate of infusion for Azithromycin for Injection, USP should be 2 mg/mL over 1 hour. Azithromycin for Injection, USP should not be given as a bolus or as an intramuscular injection.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Reconstitution</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Instructions for Use</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">These instructions for use should be made available to the individuals who perform the reconstitution steps.</content>
                        </paragraph>
                        <paragraph>Parenteral drug products should be inspected visually for particulate matter prior to administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To Open</content>
                        </paragraph>
                        <paragraph>Peel overwrap at corner and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually.</paragraph>
                        <paragraph>
                           <content styleCode="bold">To Assemble Vial and Flexible Diluent Container:</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">(Use Aseptic Technique)</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Remove the protective covers from the top of the vial and the vial port on the diluent container as follows:<list listType="unordered">
                                 <item>
                                    <caption>o</caption>To remove the breakaway vial cap, swing the pull ring over the top of the vial and pull down far enough to start the opening (See Figure 1.), then pull straight up to remove the cap. (See Figure 2.)</item>
                              </list>
                           </item>
                           <item>
                              <caption> </caption>
                              <content styleCode="bold">NOTE: </content>Once the breakaway cap has been removed, do not access vial with syringe.</item>
                        </list>
                        <paragraph>                                                      <renderMultiMedia ID="id-671412008" referencedObject="ID_0157f3be-6b16-4037-91d4-5c272f553d60"/>                                    <renderMultiMedia ID="id2094503254" referencedObject="D65E4DC8-9527-4117-8F68-E9EFFB7309A1"/>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption> </caption>
                              <list listType="unordered">
                                 <item>
                                    <caption>o</caption>To remove the vial port cover, grasp the tab on the pull ring, pull up to break the three tie strings, then pull back to remove the cover. (See Figure 3.)</item>
                              </list>
                           </item>
                           <item>
                              <caption>•</caption>Screw the vial into the vial port until it will go no further. THE VIAL MUST BE SCREWED IN TIGHTLY TO ASSURE A SEAL. This occurs approximately 1/2 turn (180°) after the first audible click. (See Figure 4.) The clicking sound does not assure a seal; the vial must be turned as far as it will go.<br/>
                              <content styleCode="bold">NOTE: </content>Once vial is seated, do not attempt to remove. (See Figure 4.)</item>
                           <item>
                              <caption>•</caption>Recheck the vial to assure that it is tight by trying to turn it further in the direction of assembly.</item>
                           <item>
                              <caption>•</caption>Label appropriately.</item>
                        </list>
                        <paragraph>                                                   <renderMultiMedia ID="id1948038831" referencedObject="C3D90E99-61DD-4425-828A-42D1BEDCA465"/>                                        <renderMultiMedia ID="id1564834218" referencedObject="ID_1885c5a7-4bb8-44f1-a83a-dbb51d12631f"/>
                        </paragraph>
                        <table width="100%">
                           <col width="100%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">To Reconstitute the Drug</content>
                                    </paragraph>
                                    <list listType="unordered">
                                       <item>
                                          <caption>•</caption>Squeeze the bottom of the diluent container gently to inflate the portion of the container surrounding the end of the drug vial.</item>
                                       <item>
                                          <caption>•</caption>With the other hand, push the drug vial down into the container telescoping the walls of the container. Grasp the inner cap of the vial through the walls of the container. (See Figure 5.)</item>
                                       <item>
                                          <caption>•</caption>
                                          <content styleCode="bold">Pull the inner cap from the drug vial. (See Figure 6.) Verify that the rubber stopper has been pulled out, allowing the drug and diluent to mix.</content>
                                       </item>
                                       <item>
                                          <caption>•</caption>Mix container contents thoroughly and use within the specified time.</item>
                                       <item>
                                          <caption>•</caption>Look through the bottom of the vial to verify that the stopper has been removed and complete mixing has occurred. (See Figure 7.)</item>
                                    </list>
                                    <paragraph>If the rubber stopper is not removed from the vial and medication is not released on the first attempt, the inner cap may be manipulated back into the rubber stopper without removing the drug vial from the diluent container. Repeat steps 3 through 5.</paragraph>
                                    <paragraph>           <renderMultiMedia ID="id-998419767" referencedObject="D1D2F98E-F8A8-499B-8FBD-BBF6941C3B22"/>                 <renderMultiMedia ID="id608083621" referencedObject="ID_1cb2fa3f-2bf4-44f6-9cad-070e5ddc645d"/>                        <renderMultiMedia ID="id-420646035" referencedObject="EB1D785F-D0CA-4B82-AE1E-0086D4101E2A"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Dilute this solution further prior to administration as instructed below.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Dilution</content>
                        </paragraph>
                        <paragraph>Azithromycin for Injection, USP ADD-Vantage<sup>®</sup> vials must be diluted prior to IV administration with the ADD-Vantage<sup>®</sup> diluent container [<content styleCode="italics">see <linkHtml href="#_RefID_2246c2cd-4d47-44e1-b594-134f22aa2">Dosage and Administration (2.3)</linkHtml>
                           </content>]. The ADD-Vantage<sup>®</sup> vial should be joined with a 250 mL ADD-Vantage<sup>®</sup> flexible diluent container (5% dextrose injection, 0.9% sodium chloride injection or 0.45% sodium chloride injection).</paragraph>
                        <paragraph>It is recommended that a 500-mg dose of Azithromycin for Injection, diluted as above, be infused over a period of not less than 60 minutes. </paragraph>
                        <paragraph>Other intravenous substances, additives, or medications should not be added to Azithromycin for Injection, or infused simultaneously through the same intravenous line.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Preparation for Administration</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">(Use Aseptic Technique)</content>
                        </paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content ID="_RefID_2246c2cd-4d47-44e1-b594-134f22aa2">Confirm the activation and admixture of vial contents.</content>
                           </item>
                           <item>
                              <caption>•</caption>Check for leaks by squeezing container firmly. If leaks are found, discard unit as sterility may be impaired.</item>
                           <item>
                              <caption>•</caption>Close flow control clamp of administration set.</item>
                           <item>
                              <caption>•</caption>Remove cover from outlet port at bottom of container.</item>
                           <item>
                              <caption>•</caption>Insert piercing pin of administration set into port with a twisting motion until the pin is firmly seated. <content styleCode="bold">NOTE:</content> See full directions on administration set carton.</item>
                           <item>
                              <caption>•</caption>Lift the free end of the hanger loop on the bottom of the vial, breaking the two tie strings. Bend the loop outward to lock it in the upright position, then suspend container from hanger.</item>
                           <item>
                              <caption>•</caption>Squeeze and release drip chamber to establish proper fluid level in chamber.</item>
                           <item>
                              <caption>•</caption>Open flow control clamp and clear air from set. Close clamp.</item>
                           <item>
                              <caption>•</caption>Attach set to venipuncture device. If device is not indwelling, prime and make venipuncture.</item>
                           <item>
                              <caption>•</caption>Regulate rate of administration with flow control clamp.</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">WARNING: Do not use flexible container in series connections.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Storage</content>
                        </paragraph>
                        <paragraph>When diluted according to the instructions (2 mg/mL), Azithromycin for Injection is stable for 24 hours at or below room temperature (30°C or 86°F), or for 7 days if stored under refrigeration (5°C or 41°F).</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                     <component>
                        <observationMedia ID="ID_0157f3be-6b16-4037-91d4-5c272f553d60">
                           <text>Figure 1</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-01.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="D65E4DC8-9527-4117-8F68-E9EFFB7309A1">
                           <text>Figure 2</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="C3D90E99-61DD-4425-828A-42D1BEDCA465">
                           <text>Figure 3</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_1885c5a7-4bb8-44f1-a83a-dbb51d12631f">
                           <text>Figure 4</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-04.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="D1D2F98E-F8A8-499B-8FBD-BBF6941C3B22">
                           <text>Figure 5</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-05.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="ID_1cb2fa3f-2bf4-44f6-9cad-070e5ddc645d">
                           <text>Figure 6</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-06.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="EB1D785F-D0CA-4B82-AE1E-0086D4101E2A">
                           <text>Figure 7</text>
                           <value mediaType="image/jpeg" xsi:type="ED">
                              <reference value="azithromycin-07.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_bf395753-4171-4040-b793-e611fb9a4330">
               <id root="a7023dc4-8df1-4bea-8f28-bcd251e572ad"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Azithromycin for Injection is supplied as white to off-white lyophilized powder in a single-dose ADD-Vantage<sup>®</sup> vial equivalent to 500 mg of azithromycin for intravenous administration.</paragraph>
               </text>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Azithromycin for Injection is supplied as white to off-white lyophilized powder in a single-dose ADD-Vantage<sup>®</sup> vial equivalent to 500 mg of azithromycin for intravenous administration. (<linkHtml href="#_RefID_bf395753-4171-4040-b793-e611fb9a4">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_10978cf1-4760-4fb8-a857-80cca0a0f108">
               <id root="1412f76f-fb02-43f6-b412-a51de9182592"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Patients with known hypersensitivity to azithromycin, erythromycin, any macrolide, or ketolide antibacterial drug. (<linkHtml href="#_RefID_6cdfd177-5986-43ae-9594-6e6ca4018">4.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin. (<linkHtml href="#_RefID_6f4698ff-38fb-405d-9e89-780290381">4.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6cdfd177-5986-43ae-9594-6e6ca40185d8">
                     <id root="f877fd06-336a-472f-9ff7-0e07eb04f019"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Azithromycin for Injection is contraindicated in patients with known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide drugs.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6f4698ff-38fb-405d-9e89-7802903812d3">
                     <id root="a27fbe3a-7e14-4160-b38c-1471bf58b75e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>4.2 Hepatic Dysfunction</title>
                     <text>
                        <paragraph>Azithromycin for Injection is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of azithromycin.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_3d5985b9-cad0-4d76-9a1b-c2da247d38fe">
               <id root="89745c06-7324-4110-8626-e069975b0893"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Serious (including fatal) allergic and skin reactions. Discontinue azithromycin and initiate appropriate therapy if reaction occurs. (<linkHtml href="#_RefS5.1">5.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Hepatotoxicity: Severe and sometimes fatal, hepatoxicity has been reported. Discontinue Azithromycin immediately if signs and symptoms of hepatitis occur. (<linkHtml href="#_RefID_184fac3d-014b-47a2-bc63-c27505ffd">5.2</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Infantile Hypertrophic Pyloric Stenosis (IHPS): Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs. (<linkHtml href="#_RefS5.3">5.3</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Prolongation of QT interval and cases of torsades de pointes have been reported. This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions and with other drugs that prolong the QT interval. (<linkHtml href="#_RefS5.4">5.4</linkHtml>) </item>
                           <item>
                              <caption>•</caption>Cardiovascular Death: Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. Consider balancing this potential risk with treatment benefits when prescribing azithromycin. (<linkHtml href="#_RefS5.5">5.5</linkHtml>)</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea: Evaluate patients if diarrhea occurs. (<linkHtml href="#_RefS5.6">5.6</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Azithromycin may exacerbate muscle weakness in persons with myasthenia gravis. (<linkHtml href="#_RefS5.7">5.7</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="cf42b9f8-8f6d-46ec-8bd6-27da7b524ab1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity</title>
                     <text>
                        <paragraph>Serious allergic reactions, including angioedema, anaphylaxis, and dermatologic reactions including Acute Generalized Exanthematous Pustulosis (AGEP),  Stevens-Johnson Syndrome and toxic epidermal necrolysis have been reported in patients on azithromycin therapy [<content styleCode="italics">see <linkHtml href="#_RefID_6cdfd177-5986-43ae-9594-6e6ca4018">Contraindications (4.1)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>Fatalities have been reported. Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have also been reported. Despite initially successful symptomatic treatment of the allergic symptoms, when symptomatic therapy was discontinued, the allergic symptoms recurred soon thereafter in some patients without further azithromycin exposure. These patients required prolonged periods of observation and symptomatic treatment. The relationship of these episodes to the long tissue half-life of azithromycin and subsequent prolonged exposure to antigen is unknown at present.</paragraph>
                        <paragraph>If an allergic reaction occurs, the drug should be discontinued and appropriate therapy should be instituted. Physicians should be aware that the allergic symptoms may reappear after symptomatic therapy has been discontinued.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_184fac3d-014b-47a2-bc63-c27505ffdbc3">
                     <id root="65c6e56d-2d8c-4613-9384-8cdd2d9a7824"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Hepatotoxicity</title>
                     <text>
                        <paragraph>Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis and hepatic failure have been reported, some of which have resulted in death. Discontinue azithromycin immediately if signs and symptoms of hepatitis occur.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="1f43a07e-46ce-45a2-949e-36005a47288d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Infantile Hypertrophic Pyloric Stenosis (IHPS)</title>
                     <text>
                        <paragraph>Following the use of azithromycin in neonates (treatment up to 42 days of life), IHPS has been reported. Direct parents and caregivers to contact their physician if vomiting or irritability with feeding occurs.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="819a1b7e-6347-4f22-b9cd-b1b0102c3af8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 QT Prolongation</title>
                     <text>
                        <paragraph>Prolonged cardiac repolarization and QT interval, imparting a risk of developing cardiac arrhythmia and torsades de pointes, have been seen with treatment with macrolides, including azithromycin. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving azithromycin. Providers should consider the risk of QT prolongation, which can be fatal when weighing the risks and benefits of azithromycin for at-risk groups including:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content ID="_RefS5.4">patients with known prolongation of the QT interval, a history of torsades de pointes, congenital long QT syndrome, bradyarrhythmias or uncompensated heart failure</content>
                           </item>
                           <item>
                              <caption>•</caption>patients on drugs known to prolong the QT interval</item>
                           <item>
                              <caption>•</caption>patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.</item>
                        </list>
                        <paragraph>Elderly patients may be more susceptible to drug-associated effects on the QT interval.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="60ece596-5147-4ce9-bb9f-1d737f7a2afa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5	Cardiovascular Death</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Some observational studies have shown an approximately two-fold increased short-term potential risk of acute cardiovascular death in adults exposed to azithromycin relative to other antibacterial drugs, including amoxicillin. The five-day cardiovascular mortality observed in these studies ranged from 20 to 400 per million azithromycin treatment courses. This potential risk was noted to be greater during the first five days of azithromycin use and does not appear to be limited to those patients with preexisting cardiovascular diseases. The data in these observational studies are insufficient to establish or exclude a causal relationship between acute cardiovascular death and azithromycin use. Consider balancing this potential risk with treatment benefits when prescribing azithromycin.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.6">
                     <id root="48cef1e8-b015-4e44-978d-22ab6738ab7a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 <content styleCode="italics">Clostridioides difficile</content>-Associated Diarrhea</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridioides difficile </content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Azithromycin for Injection and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <content styleCode="italics">C. difficile</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">C. difficile </content>produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of <content styleCode="italics">C. difficile </content>cause increased morbidity and mortality, as these infections can be refractory to antibacterial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</paragraph>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibacterial use not directed against <content styleCode="italics">C. difficile </content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <content styleCode="italics">C. difficile</content> and surgical evaluation should be instituted as clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.7">
                     <id root="64bb072c-7c0b-4ab2-91f5-88d5de8edd6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Exacerbation of Myasthenia Gravis</title>
                     <text>
                        <paragraph>Exacerbations of symptoms of myasthenia gravis and new onset of myasthenic syndrome have been reported in patients receiving azithromycin therapy.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.8">
                     <id root="7d13b206-2398-4e3f-921a-e9a8c0e20ba4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Infusion Site Reactions</title>
                     <text>
                        <paragraph>Azithromycin for Injection should be reconstituted and diluted as directed and administered as an intravenous infusion over not less than 60 minutes [<content styleCode="italics">see <linkHtml href="#ID_2246c2cd-4d47-44e1-b594-134f22aa22bd">Dosage and Administration (2)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Local IV site reactions have been reported with the intravenous administration of azithromycin. The incidence and severity of these reactions were the same when 500 mg azithromycin was given over 1 hour (2 mg/mL as 250 mL infusion) or over 3 hours (1 mg/mL as 500 mL infusion) [<content styleCode="italics">see <linkHtml href="#_RefID_4dcc79ab-f87d-4b80-b76d-64248db5a">Adverse Reactions (6)</linkHtml>
                           </content>]<content styleCode="italics">. </content>All volunteers who received infusate concentrations above 2 mg/mL experienced local IV site reactions and, therefore, higher concentrations should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.9">
                     <id root="b184516d-e7ac-4589-a1d4-119a93886502"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing Azithromycin for Injection in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_4dcc79ab-f87d-4b80-b76d-64248db5a3eb">
               <id root="993dab72-6a65-4467-9066-a956ab3afc00"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in labeling:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content ID="_RefID_4dcc79ab-f87d-4b80-b76d-64248db5a">Hypersensitivity <content styleCode="italics">[see <linkHtml href="#_RefS5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                        </content>
                     </item>
                     <item>
                        <caption>•</caption>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#_RefID_184fac3d-014b-47a2-bc63-c27505ffd">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Infantile Hypertrophic Pyloric Stenosis (IHPS) <content styleCode="italics">[see <linkHtml href="#_RefS5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>QT Prolongation <content styleCode="italics">[see <linkHtml href="#_RefS5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Cardiovascular Death <content styleCode="italics">[see <linkHtml href="#_RefS5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="italics">Clostridioides difficile-</content>Associated Diarrhea (CDAD) <content styleCode="italics">[see <linkHtml href="#_RefS5.6">Warnings and Precautions (5.6)</linkHtml>]</content>
                     </item>
                     <item>
                        <caption>•</caption>Exacerbation of Myasthenia Gravis <content styleCode="italics">[see <linkHtml href="#_RefS5.7">Warnings and Precautions (5.7)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions are nausea (4%), diarrhea (4%), abdominal pain (3%), or vomiting (1%). (<linkHtml href="#_RefID_4dcc79ab-f87d-4b80-b76d-64248db5a">6</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_eda71f6f-0f28-4a5c-9c4f-085aa6b73fe2">
                     <id root="1080f042-ee81-43b4-a63d-1bc84bcfbee5"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>In clinical trials of intravenous azithromycin for community-acquired pneumonia, in which 2 to 5 IV doses were given, the reported adverse reactions were mild to moderate in severity and were reversible upon discontinuation of the drug. The majority of patients in these trials had one or more co-morbid diseases and were receiving concomitant medications. Approximately 1.2% of the patients discontinued intravenous Azithromycin for Injection therapy, and a total of 2.4% discontinued azithromycin therapy by either the intravenous or oral route because of clinical or laboratory side effects.</paragraph>
                        <paragraph>In clinical trials conducted in patients with pelvic inflammatory disease, in which 1 to 2 IV doses were given, 2% of women who received monotherapy with azithromycin and 4% who received azithromycin plus metronidazole discontinued therapy due to clinical side effects.</paragraph>
                        <paragraph>Clinical adverse reactions leading to discontinuations from these studies were gastrointestinal (abdominal pain, nausea, vomiting, diarrhea) and rashes; laboratory side effects leading to discontinuation were increases in transaminase levels and/or alkaline phosphatase levels.</paragraph>
                        <paragraph>Overall, the most common adverse reactions associated with treatment in adult patients who received IV/Oral Azithromycin in studies of community-acquired pneumonia were related to the gastrointestinal system with diarrhea/loose stools (4.3%), nausea (3.9%), abdominal pain (2.7%) and vomiting (1.4%) being the most frequently reported.</paragraph>
                        <paragraph>Approximately 12% of patients experienced a side effect related to the intravenous infusion; most common were pain at the injection site (6.5%) and local inflammation (3.1%).</paragraph>
                        <paragraph>The most common adverse reactions associated with treatment in adult women who received IV/Oral Azithromycin in trials of pelvic inflammatory disease were related to the gastrointestinal system. Diarrhea (8.5%) and nausea (6.6%) were most commonly reported, followed by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus (1.9%). When azithromycin was co-administered with metronidazole in these trials, a higher proportion of women experienced adverse reactions of nausea (10.3%), abdominal pain (3.7%), vomiting (2.8%), infusion site reaction, stomatitis, dizziness, or dyspnea (all at 1.9%).</paragraph>
                        <paragraph>Adverse reactions that occurred with a frequency of 1% or less included the following:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gastrointestinal: </content>Dyspepsia, flatulence, mucositis, oral moniliasis and gastritis. <br/>
                           <content styleCode="bold">Nervous system: </content>Headache, somnolence.<br/>
                           <content styleCode="bold">Allergic: </content>Bronchospasm.<br/>
                           <content styleCode="bold">Special senses: </content>Taste perversion.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0ac17118-5a76-43cb-a761-639d1fc832fe">
                     <id root="162dadc8-116b-49cd-92b4-753640e56f18"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of azithromycin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>Adverse reactions reported with azithromycin during the postmarketing period in adult and/or pediatric patients for which a causal relationship may not be established include:</paragraph>
                        <paragraph>
                           <content styleCode="bold">Allergic:</content> Arthralgia, edema, urticaria and angioedema.<br/>
                           <content styleCode="bold">Cardiovascular:</content> Arrhythmias including ventricular tachycardia and hypotension. There have been reports of QT prolongation, torsades de pointes, and cardiovascular death.<br/>
                           <content styleCode="bold">Gastrointestinal:</content> Anorexia, constipation, dyspepsia, flatulence, vomiting/diarrhea, pseudomembranous colitis, pancreatitis, oral candidiasis, pyloric stenosis, and reports of tongue discoloration.<br/>
                           <content styleCode="bold">General:</content> Asthenia, paresthesia, fatigue, malaise and anaphylaxis (including fatalities).<br/>
                           <content styleCode="bold">Genitourinary:</content> Interstitial nephritis and acute renal failure and vaginitis.<br/>
                           <content styleCode="bold">Hematopoietic:</content> Thrombocytopenia.<br/>
                           <content styleCode="bold">Liver/biliary:</content> Abnormal liver function, hepatitis, cholestatic jaundice, hepatic necrosis, and hepatic failure [<content styleCode="italics">see <linkHtml href="#_RefID_184fac3d-014b-47a2-bc63-c27505ffd">Warnings and Precautions (5.2)</linkHtml>
                           </content>].<br/>
                           <content styleCode="bold">Nervous system:</content> Convulsions, dizziness/vertigo, headache, somnolence, hyperactivity, nervousness, agitation and syncope.<br/>
                           <content styleCode="bold">Psychiatric:</content> Aggressive reaction and anxiety.<br/>
                           <content styleCode="bold">Skin/appendages:</content> Pruritus, serious skin reactions including, erythema multiforme, AGEP, Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.<br/>
                           <content styleCode="bold">Special senses: </content>Hearing disturbances including hearing loss, deafness and/or tinnitus and reports of taste/smell perversion and/or loss.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_221870fa-0734-4e41-969a-f442b6d677d1">
                     <id root="d1df7a06-c202-4483-9038-378009a48534"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Laboratory Abnormalities</title>
                     <text>
                        <paragraph>Significant abnormalities (irrespective of drug relationship) occurring during the clinical trials were reported as follows:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>elevated ALT (SGPT), AST (SGOT), creatinine (4 to 6%)</item>
                           <item>
                              <caption>•</caption>elevated LDH, bilirubin (1 to 3%)</item>
                           <item>
                              <caption>•</caption>leukopenia, neutropenia, decreased platelet count, and elevated serum alkaline phosphatase (less than 1%)</item>
                        </list>
                        <paragraph>When follow-up was provided, changes in laboratory tests appeared to be reversible.</paragraph>
                        <paragraph>In multiple-dose clinical trials involving more than 750 patients treated with azithromycin (IV/Oral), less than 2% of patients discontinued azithromycin therapy because of treatment-related liver enzyme abnormalities.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_03064c8b-24d2-424c-9a70-b46e10138b57">
               <id root="e728b96e-fbe6-44fb-ba66-d675e7650ff9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Nelfinavir: Close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted. (<linkHtml href="#_RefID_0f73a128-0846-46df-a156-ba67b068d">7.1</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Warfarin: Use with azithromycin may increase coagulation times; monitor prothrombin time. (<linkHtml href="#_RefID_b3706b62-b516-4dd2-8e64-9d08f3636">7.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0f73a128-0846-46df-a156-ba67b068dee3">
                     <id root="7863d25e-37b1-4bb5-935f-285443c7f448"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Nelfinavir</title>
                     <text>
                        <paragraph>Co-administration of nelfinavir at steady-state with a single oral dose of azithromycin resulted in increased azithromycin serum concentrations. Although a dose adjustment of azithromycin is not recommended when administered in combination with nelfinavir, close monitoring for known adverse reactions of azithromycin, such as liver enzyme abnormalities and hearing impairment, is warranted [<content styleCode="italics">see <linkHtml href="#_RefID_4dcc79ab-f87d-4b80-b76d-64248db5a">Adverse Reactions (6)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b3706b62-b516-4dd2-8e64-9d08f36363ab">
                     <id root="2ddc9a07-eb13-43a7-a0e4-051a89a22f3c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Warfarin</title>
                     <text>
                        <paragraph>Spontaneous postmarketing reports suggest that concomitant administration of azithromycin may potentiate the effects of oral anticoagulants such as warfarin, although the prothrombin time was not affected in the dedicated drug interaction study with azithromycin and warfarin. Prothrombin times should be carefully monitored while patients are receiving azithromycin and oral anticoagulants concomitantly.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_83b2fb0a-2f21-4048-88ce-bd5cdfce9945">
                     <id root="35ef2190-92e6-404f-a3cf-d35db6364a27"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Potential Drug-Drug Interaction with Macrolides</title>
                     <text>
                        <paragraph>Interactions with digoxin, colchicine or phenytoin have not been reported in clinical trials with azithromycin. No specific drug interaction studies have been performed to evaluate potential drug-drug interaction. However, drug interactions have been observed with other macrolide products. Until further data are developed regarding drug interactions when digoxin, colchicine or phenytoin are used with azithromycin careful monitoring of patients is advised.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_9113f1c3-1cb7-4c56-98b8-93a6dad511fe">
               <id root="e0a716a6-a7b5-4da3-839b-97920eec968d"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20220203"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Pediatric use: Safety and effectiveness in the treatment of patients under 16 years of age have not been established. (<linkHtml href="#_RefID_f2635391-1953-460a-af64-a89f06386">8.4</linkHtml>)</item>
                           <item>
                              <caption>•</caption>Geriatric use: Elderly patients may be more susceptible to development of torsades de pointes arrhythmias. (<linkHtml href="#_RefID_7b72b8a8-53f5-460c-a5d3-293837a3a">8.5</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_0067656a-703b-4fbd-9270-62caf5e781e4">
                     <id root="7b4ef95a-c82c-4b65-b385-8b5640286f71"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20220203"/>
                     <component>
                        <section ID="ID_16ac29e2-e7e0-4a29-88f7-846f94d29b0c">
                           <id root="a0285b5e-7e3d-4ef4-9ed1-f18d15217f5d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Available data from published literature and postmarketing experience over several decades with azithromycin use in pregnant women have not identified any drug-associated risks for major birth defects, miscarriage, or adverse maternal or fetal outcomes <content styleCode="italics">(see <linkHtml href="#refdata">Data</linkHtml>).</content> Developmental toxicity studies with azithromycin in rats, mice, and rabbits showed no drug-induced fetal malformations at doses up to 4, 2, and 2 times, respectively, an adult human daily dose of 500 mg based on body surface area. Decreased viability and delayed development were observed in the offspring of pregnant rats administered azithromycin from day 6 of pregnancy through weaning at a dose equivalent to 4 times an adult human daily dose of 500 mg based on body surface area <content styleCode="italics">(see <linkHtml href="#refdata">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data1">
                           <id root="99c97cf2-bc18-4175-be54-961b900f262d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="refdata">
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                           <component>
                              <section ID="ID_2e9d851b-ea28-4b40-a169-06c3449252be">
                                 <id root="6a4ab7f9-d107-4c2e-82f5-f4284ac70897"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                    </paragraph>
                                    <paragraph>Available data from published observational studies, case series and case reports over several decades do not suggest an increased risk for major birth defects, miscarriage or adverse maternal or fetal outcomes with azithromycin use in pregnant women. Limitations of these data include the lack of randomization and inability to control for confounders such as underlying maternal disease and maternal use of concomitant medications.</paragraph>
                                 </text>
                                 <effectiveTime value="20220203"/>
                              </section>
                           </component>
                           <component>
                              <section ID="ID_6d4d7df4-6308-4f41-83c7-ca524056d0cd">
                                 <id root="701818f4-7cf0-45c6-99d1-348aea4eb8b0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Reproductive and developmental toxicology studies have not been conducted using IV administration of azithromycin to animals. Azithromycin administered during the period of organogenesis did not cause fetal malformations in rats and mice at oral doses up to 200 mg/kg/day (moderately maternally toxic). Based on body surface area, this dose is approximately 4 (rats) and 2 (mice) times an adult human daily dose of 500 mg. In rabbits administered azithromycin at oral doses of 10, 20 and 40 mg/kg/day during organogenesis, reduced maternal body weight and food consumption were observed in all groups; no evidence of fetotoxicity or teratogenicity was observed at these doses, the highest of which is estimated to be 2 times an adult human daily dose of 500 mg based on body surface area.</paragraph>
                                    <paragraph>In a pre- and postnatal development study, azithromycin was administered orally to pregnant rats from day 6 of pregnancy until weaning at doses of 50 or 200 mg/kg/day. Maternal toxicity (reduced food consumption and body weight gain; increased stress at parturition) was observed at the higher dose. Effects in the offspring were noted at 200 mg/kg/day during the postnatal development period (decreased viability, delayed developmental landmarks). These effects were not observed in a pre- and postnatal rat study when up to 200 mg/kg/day of azithromycin was given orally beginning on day 15 of pregnancy until weaning.</paragraph>
                                 </text>
                                 <effectiveTime value="20220203"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="31be2086-a037-4599-a299-d480ec7a8a19"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20220203"/>
                     <component>
                        <section ID="ID_1c1ae70b-56de-4029-98f7-942a4147d582">
                           <id root="60006f26-7109-4a26-8012-a8e7899ce188"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Azithromycin is present in human milk <content styleCode="italics">(see <linkHtml href="#refclinical">Clinical Considerations</linkHtml>)</content>. Non-serious adverse reactions have been reported in breastfed infants after maternal administration of azithromycin <content styleCode="italics">(see <linkHtml href="#refclinical">Clinical Considerations</linkHtml>)</content>. There are no available data on the effects of azithromycin on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for azithromycin and any potential adverse effects on the breastfed infant from azithromycin or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Clinical">
                           <id root="b805c0df-137d-4e47-91f9-b3d61f169f71"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph ID="refclinical">
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Advise women to monitor the breastfed infant for diarrhea, vomiting, or rash.</paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data2">
                           <id root="2aa35bd9-a83c-49a3-81c4-fe4265f6a8d2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Azithromycin breastmilk concentrations were measured in 20 women after receiving a single 2 g oral dose of azithromycin during labor. Breastmilk samples collected on days 3 and 6 postpartum as well  as 2 and 4 weeks postpartum revealed the presence of azithromycin in breastmilk up to 4 weeks after dosing. In another study, a single dose of azithromycin 500 mg was administered intravenously to 8 women prior to incision for cesarean section. Breastmilk (colostrum) samples obtained between 12 and 48 hours after dosing revealed that azithromycin persisted in breastmilk up to 48 hours.</paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_f2635391-1953-460a-af64-a89f0638654e">
                     <id root="fea49684-c25f-44b8-9438-ec1ad1e3c967"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of azithromycin for injection in children or adolescents under 16 years have not been established. In controlled clinical studies, azithromycin has been administered to pediatric patients (age 6 months to 16 years) by the oral route. For information regarding the use of azithromycin for oral suspension in the treatment of pediatric patients, [<content styleCode="italics">see <linkHtml href="#S1.3">Indications and Usage (1)</linkHtml> and <linkHtml href="#ID_2246c2cd-4d47-44e1-b594-134f22aa22bd">Dosage and Administration (2)</linkHtml>
                           </content>] of the prescribing information for Azithromycin for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_7b72b8a8-53f5-460c-a5d3-293837a3aadc">
                     <id root="45c10ab4-9373-45af-9f35-893e10c9cd8b"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of azithromycin following oral administration in older volunteers (65–85 years old) were similar to those in younger volunteers (18–40 years old) for the 5-day therapeutic regimen.</paragraph>
                        <paragraph>In multiple-dose clinical trials of intravenous azithromycin in the treatment of community-acquired pneumonia, 45% of patients (188/414) were at least 65 years of age and 22% of patients (91/414) were at least 75 years of age. No overall differences in safety were observed between these subjects and younger subjects in terms of adverse reactions, laboratory abnormalities and discontinuations. Similar decreases in clinical response were noted in azithromycin- and comparator-treated patients with increasing age.</paragraph>
                        <paragraph>Azithromycin for Injection contains 114 mg (4.96 mEq) of sodium per vial. At the usual recommended doses, patients would receive 114 mg (4.96 mEq) of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. The total sodium content from dietary and non-dietary sources may be clinically important with regard to such diseases as congestive heart failure.</paragraph>
                        <paragraph>Elderly patients may be more susceptible to development of torsades de pointes arrhythmia than younger patients [<content styleCode="italics">see <linkHtml href="#_RefS5.4">Warnings and Precautions (5.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_23aa0323-c18e-4bbc-a5be-9b008e62632b">
               <id root="638dbcf0-4ad0-47a9-8c23-3adcbbb3c9ff"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Adverse reactions experienced in higher than recommended doses were similar to those seen at normal doses particularly nausea, diarrhea and vomiting. In the event of overdosage, general symptomatic and supportive measures are indicated as required.</paragraph>
               </text>
               <effectiveTime value="20220203"/>
            </section>
         </component>
         <component>
            <section ID="ID_7db370bc-0a35-46a2-9b8e-ddd493b2f0e6">
               <id root="9ac86932-fb28-42da-99af-c9150cfc9a2f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Azithromycin for Injection, USP contains the active ingredient azithromycin, an azalide, a subclass of macrolide antibiotics, for intravenous injection. Azithromycin has the chemical name (<content styleCode="italics">2R,3S,4R,5R,8R,10R,11R,12S,13S,14R</content>)-13-[(2,6-dideoxy-3-<content styleCode="italics">C</content>-methyl-3-<content styleCode="italics">O</content>-methyl-α-<content styleCode="italics">L-ribo</content>-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-hepta-methyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-<content styleCode="italics">D</content>-<content styleCode="italics">xylo</content>-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub>, and its molecular weight is 749. Azithromycin has the following structural formula:</paragraph>
                  <renderMultiMedia ID="id-1344699979" referencedObject="CB2CC28D-4930-48B5-99BC-02581A172BD5"/>
                  <paragraph>Azithromycin, as the monohydrate, is a white crystalline powder with a molecular formula of C<sub>38</sub>H<sub>72</sub>N<sub>2</sub>O<sub>12</sub> ∙ H<sub>2</sub>O and a molecular weight of 767.</paragraph>
                  <paragraph>Azithromycin for Injection, USP consists of azithromycin monohydrate and the following inactive ingredients: anhydrous citric acid and sodium hydroxide. Sodium hydroxide is added to adjust the pH. Azithromycin for Injection, USP is supplied as white to off-white lyophilized powder in a single-dose ADD-Vantage<sup>®</sup> vial for intravenous administration only after reconstitution, according to directions in the <content styleCode="italics">
                        <linkHtml href="#ID_2246c2cd-4d47-44e1-b594-134f22aa22bd">Dosage and Administration</linkHtml>
                     </content> section. Each ADD-Vantage<sup>®</sup> vial contains azithromycin monohydrate equivalent to 500 mg azithromycin, 392 mg anhydrous citric acid and sodium hydroxide for pH adjustment.</paragraph>
               </text>
               <effectiveTime value="20220203"/>
               <component>
                  <observationMedia ID="CB2CC28D-4930-48B5-99BC-02581A172BD5">
                     <text>Azithromycin Structural Formula</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="azithromycin-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_adb24df1-6446-4be4-b2a5-76959b3ea153">
               <id root="41981641-51ab-4cd3-91ae-c3a84b13d930"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220203"/>
               <component>
                  <section ID="ID_bf330380-2538-489b-affe-c173018fa655">
                     <id root="593bed0e-0285-4acd-ad98-55155ae127c9"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Azithromycin is a macrolide antibacterial drug [<content styleCode="italics">see <linkHtml href="#_RefID_9a869950-5c90-4e7a-9f33-e507fe17c">Microbiology (12.4)</linkHtml>
                           </content>].</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0e595df5-b350-48c6-b4f5-bf66c5778b29">
                     <id root="3956daeb-242c-49c2-a828-0e36533c4eb2"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Based on animal models of infection, the antibacterial activity of azithromycin appears to correlate with the ratio of area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC) for certain pathogens (<content styleCode="italics">S. pneumoniae </content>and<content styleCode="italics"> S. aureus</content>). The principal pharmacokinetic/pharmacodynamic parameter best associated with clinical and microbiological cure has not been elucidated in clinical trials with azithromycin.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Cardiac Electrophysiology</content>
                           </content>
                        </paragraph>
                        <paragraph>QTc interval prolongation was studied in a randomized, placebo-controlled parallel trial in 116 healthy subjects who received either chloroquine (1,000 mg) alone or in combination with oral azithromycin (500 mg, 1,000 mg, and 1,500 mg once daily). Co-administration of azithromycin increased the QTc interval in a dose- and concentration- dependent manner. In comparison to chloroquine alone, the maximum mean (95% upper confidence bound) increases in QTcF were 5 (10) ms, 7 (12) ms and 9 (14) ms with the co-administration of 500 mg, 1,000 mg and 1,500 mg azithromycin, respectively.</paragraph>
                        <paragraph>Since the mean C<sub>max</sub> of azithromycin following a 500 mg IV dose given over 1 hour is higher than the mean C<sub>max</sub> of azithromycin following the administration of a 1,500 mg oral dose, it is possible that QTc may be prolonged to a greater extent with IV azithromycin at close proximity to a one hour infusion of 500 mg.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_df229571-1c41-4ddb-b6ab-9aecf38169ba">
                     <id root="0fd4fcda-486c-4b87-9fff-bfd0d75f379a"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics </title>
                     <text>
                        <paragraph>In patients hospitalized with community-acquired pneumonia receiving single daily one-hour intravenous infusions for 2 to 5 days of 500-mg azithromycin at a concentration of 2 mg/mL, the mean C<sub>max</sub> ± S.D. achieved was 3.63 ± 1.60 mcg/mL, while the 24-hour trough level was 0.20 ± 0.15 mcg/mL and the AUC<sub>24</sub> was 9.60 ± 4.80 mcg∙h/mL.</paragraph>
                        <paragraph>The mean C<sub>max</sub>, 24-hour trough and AUC<sub>24</sub> values were 1.14 ± 0.14 mcg/mL, 0.18 ± 0.02 mcg/mL and 8.03 ±0.86 mcg∙ h/mL, respectively, in normal volunteers receiving a 3-hour intravenous infusion of 500 mg azithromycin at a concentration of 1 mg/mL. Similar pharmacokinetic values were obtained in patients hospitalized with community-acquired pneumonia who received the same 3-hour dosage regimen for 2–5 days.</paragraph>
                        <table width="100%">
                           <col width="15%"/>
                           <col width="14%"/>
                           <col width="14%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <col width="8%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="10" valign="top">
                                    <sup>a</sup> 500 mg (2 mg/mL) for 2-5 days in community-acquired pneumonia patients.<br/>
                                    <sup>b</sup> 500 mg (1 mg/mL) for 5 days in healthy subjects.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Infusion Concentration, Duration</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="9" styleCode="Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Time after starting the infusion (hr)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">  </content>
                                       <br/>
                                       <content styleCode="bold">0.5</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">1</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">2</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">3</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">4</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">6</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">8</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">12</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">  </content>
                                       <br/>
                                       <content styleCode="bold">24</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">2 mg/mL, 1 hr<sup>a</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>2.98 ±1.12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>3.63 ±1.73</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.60 ±0.31</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.40 ±0.23</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.33 ±0.16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.26 ±0.14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.27 ±0.15</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>0.20 ±0.12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>0.20 ±0.15</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">1 mg/mL, 3 hr<sup>b</sup>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0.91 ±0.13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1.02 ±0.11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1.14 ±0.13</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>1.13 ±0.16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0.32 ±0.05</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0.28 ±0.04</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0.27 ±0.03</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="bottom">
                                    <paragraph>0.22 ±0.02</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="bottom">
                                    <paragraph>0.18 ±0.02</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Comparison of the plasma pharmacokinetic parameters following the 1st and 5th daily doses of 500 mg intravenous azithromycin showed only an 8% increase in C<sub>max</sub> but a 61% increase in AUC<sub>24</sub> reflecting a threefold rise in C<sub>24</sub> trough levels.</paragraph>
                        <paragraph>Following single-oral doses of 500 mg azithromycin (two 250 mg capsules) to 12 healthy volunteers, C<sub>max</sub>, trough level and AUC<sub>24</sub> were reported to be 0.41 mcg/mL, 0.05 mcg/mL and 2.6 mcg∙h/mL, respectively. These oral values are approximately 38%, 83% and 52% of the values observed following a single 500-mg I.V. 3-hour infusion (C<sub>max</sub>: 1.08 mcg/mL, trough: 0.06 mcg/mL and AUC<sub>24</sub>: 5 mcg∙h/mL). Thus, plasma concentrations are higher following the intravenous regimen throughout the 24-hour interval.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Distribution</content>
                           </content>
                        </paragraph>
                        <paragraph>The serum protein binding of azithromycin is variable in the concentration range approximating human exposure, decreasing from 51% at 0.02 mcg/mL to 7% at 2 mcg/mL.</paragraph>
                        <paragraph>Tissue concentrations have not been obtained following intravenous infusions of azithromycin, but following oral administration in humans azithromycin has been shown to penetrate into tissues, including skin, lung, tonsil and cervix.</paragraph>
                        <paragraph>Tissue levels were determined following a single oral dose of 500-mg azithromycin in 7 gynecological patients. Approximately 17 hours after dosing, azithromycin concentrations were 2.7 mcg/g in ovarian tissue, 3.5 mcg/g in uterine tissue and 3.3 mcg/g in salpinx. Following a regimen of 500 mg on the first day followed by 250 mg daily for 4 days, concentrations in the cerebrospinal fluid were less than 0.01 mcg/mL in the presence of non-inflamed meninges.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Metabolism</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro </content>and <content styleCode="italics">in vivo </content>studies to assess the metabolism of azithromycin have not been performed.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Elimination</content>
                           </content>
                        </paragraph>
                        <paragraph>Plasma concentrations of azithromycin following single 500-mg oral and IV doses declined in a polyphasic pattern with a mean apparent plasma clearance of 630 mL/min and terminal elimination half-life of 68 hours. The prolonged terminal half-life is thought to be due to extensive uptake and subsequent release of drug from tissues.</paragraph>
                        <paragraph>In a multiple-dose study in 12 normal volunteers utilizing a 500-mg (1 mg/mL) one-hour intravenous-dosage regimen for five days, the amount of administered azithromycin dose excreted in urine in 24 hours was about 11% after the 1st dose and 14% after the 5<sup>th </sup>dose. These values are greater than the reported 6% excreted unchanged in urine after oral administration of azithromycin. Biliary excretion is a major route of elimination for unchanged drug, following oral administration.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Specific Populations</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Azithromycin pharmacokinetics were investigated in 42 adults (21 to 85 years of age) with varying degrees of renal impairment. Following the oral administration of a single 1,000-mg dose of azithromycin, mean C<sub>max</sub> and AUC<sub>0–120</sub> increased by 5.1% and 4.2%, respectively in subjects with mild to moderate renal impairment (GFR 10 to 80 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min). The mean C<sub>max</sub> and AUC<sub>0–120</sub> increased 61% and 35%, respectively in subjects with severe renal impairment (GFR &lt;10 mL/min) compared to subjects with normal renal function (GFR &gt;80 mL/min).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of azithromycin in subjects with hepatic impairment has not been established.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Male and Female Patients</content>
                        </paragraph>
                        <paragraph>There are no significant differences in the disposition of azithromycin between male and female subjects. No dosage adjustment is recommended based on gender.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Geriatric Patients</content>
                        </paragraph>
                        <paragraph>Pharmacokinetic studies with intravenous azithromycin have not been performed in older volunteers. Pharmacokinetics of azithromycin following oral administration in older volunteers (65–85 years old) were similar to those in younger volunteers (18–40 years old) for the 5-day therapeutic regimen [<content styleCode="italics">see <linkHtml href="#_RefID_7b72b8a8-53f5-460c-a5d3-293837a3a">Geriatric Use (8.5)</linkHtml>
                           </content>].</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>Pharmacokinetic studies with intravenous azithromycin have not been performed in children.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>Drug interaction studies were performed with oral azithromycin and other drugs likely to be co-administered. The effects of co-administration of azithromycin on the pharmacokinetics of other drugs are shown in <linkHtml href="#_Ref405809122">Table 1</linkHtml> and the effects of other drugs on the pharmacokinetics of azithromycin are shown in <linkHtml href="#_Ref405809172">Table 2</linkHtml>.</paragraph>
                        <paragraph>Co-administration of azithromycin at therapeutic doses had a modest effect on the pharmacokinetics of the drugs listed in <linkHtml href="#_Ref405809122">Table 1</linkHtml>. No dosage adjustment of drugs listed in <linkHtml href="#_Ref405809122">Table 1</linkHtml> is recommended when co-administered with azithromycin.</paragraph>
                        <paragraph>Co-administration of azithromycin with efavirenz or fluconazole had a modest effect on the pharmacokinetics of azithromycin. Nelfinavir significantly increased the C<sub>max</sub> and AUC of azithromycin. No dosage adjustment of azithromycin is recommended when administered with drugs listed in <linkHtml href="#_Ref405809172">Table 2</linkHtml> [<content styleCode="italics">see <linkHtml href="#_RefID_83b2fb0a-2f21-4048-88ce-bd5cdfce9">Drug Interactions (7.3)</linkHtml>
                           </content>]<content styleCode="italics">.</content>
                        </paragraph>
                        <table ID="_Ref405809122" width="100%">
                           <caption>Table 1. Drug Interactions: Pharmacokinetic Parameters for Co-administered Drugs in the Presence of Azithromycin</caption>
                           <col width="19%"/>
                           <col width="20%"/>
                           <col width="20%"/>
                           <col width="5%"/>
                           <col width="18%"/>
                           <col width="20%"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Co-administered Drug</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of </content>
                                       <br/>
                                       <content styleCode="bold">Co-administered Drug</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of </content>
                                       <br/>
                                       <content styleCode="bold">Azithromycin</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Ratio (with/without azithromycin) of </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Co-administered Drug Pharmacokinetic </content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">Parameters (90% CI); No Effect = 1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Mean C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Mean AUC</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Atorvastatin</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10 mg/day for 8 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg/day orally on days 6-8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.83</paragraph>
                                    <paragraph>(0.63 to 1.08)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.01</paragraph>
                                    <paragraph>(0.81 to 1.25)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Carbamazepine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>200 mg/day for 2 days, then 200 mg twice a day for 18 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg/day orally for days 16-18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.97</paragraph>
                                    <paragraph>(0.88 to 1.06)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.96</paragraph>
                                    <paragraph>(0.88 to 1.06)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Cetirizine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>20 mg/day for 11 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg orally on day 7, then 250 mg/day on days 8-11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.03</paragraph>
                                    <paragraph>(0.93 to 1.14)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.02</paragraph>
                                    <paragraph>(0.92 to 1.13)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Didanosine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>200 mg orally twice a day for 21 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,200 mg/day orally</paragraph>
                                    <paragraph>on days 8-21</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.44</paragraph>
                                    <paragraph>(0.85 to 2.43)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.14</paragraph>
                                    <paragraph>(0.83 to 1.57)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Efavirenz</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>400 mg/day for 7 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>600 mg orally on day 7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.04<footnote ID="_Ref405807560">- 90% Confidence interval not reported</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.95<footnoteRef IDREF="_Ref405807560"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Fluconazole</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>200 mg orally single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,200 mg orally single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.04</paragraph>
                                    <paragraph>(0.98 to 1.11)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.01</paragraph>
                                    <paragraph>(0.97 to 1.05)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Indinavir</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>800 mg three times a day for 5 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,200 mg orally on day 5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.96</paragraph>
                                    <paragraph>(0.86 to 1.08)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.9</paragraph>
                                    <paragraph>(0.81 to 1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Midazolam</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>15 mg orally on day 3</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg/day orally for 3 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.27</paragraph>
                                    <paragraph>(0.89 to 1.81)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.26</paragraph>
                                    <paragraph>(1.01 to 1.56)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Nelfinavir</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>750 mg three times a day for 11 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,200 mg orally on day 9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.9</paragraph>
                                    <paragraph>(0.81 to 1.01)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.85</paragraph>
                                    <paragraph>(0.78 to 0.93)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Sildenafil</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>100 mg on days 1 and 4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg/day orally for 3 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.16</paragraph>
                                    <paragraph>(0.86 to 1.57)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.92</paragraph>
                                    <paragraph>(0.75 to 1.12)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Theophylline</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>4 mg/kg IV on days 1, 11, 25</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg orally on day 7,</paragraph>
                                    <paragraph>250 mg/day on days</paragraph>
                                    <paragraph>8-11</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.19</paragraph>
                                    <paragraph>(1.02 to 1.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.02</paragraph>
                                    <paragraph>(0.86 to 1.22)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Theophylline</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>300 mg orally twice a day for 15 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg orally on day 6, then 250 mg/day on days 7-10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.09</paragraph>
                                    <paragraph>(0.92 to 1.29)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.08</paragraph>
                                    <paragraph>(0.89 to 1.31)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Triazolam</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.125 mg on day 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg orally on day 1,</paragraph>
                                    <paragraph>then 250 mg/day on day 2</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.06<footnoteRef IDREF="_Ref405807560"/>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>1.02<footnoteRef IDREF="_Ref405807560"/>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Trimethoprim/</paragraph>
                                    <paragraph>Sulfamethoxazole</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>160 mg/800 mg/day orally for 7 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1,200 mg orally on day 7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>0.85</paragraph>
                                    <paragraph>(0.75 to 0.97)/</paragraph>
                                    <paragraph>0.9</paragraph>
                                    <paragraph>(0.78 to 1.03)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.87</paragraph>
                                    <paragraph>(0.8 to 0.95)/</paragraph>
                                    <paragraph>0.96</paragraph>
                                    <paragraph>(0.88 to 1.03)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Zidovudine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>500 mg/day orally for 21 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>600 mg/day orally for 14 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>1.12</paragraph>
                                    <paragraph>(0.42 to 3.02)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="top">
                                    <paragraph>0.94</paragraph>
                                    <paragraph>(0.52 to 1.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="top">
                                    <paragraph>Zidovudine</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>500 mg/day orally for 21 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>1,200 mg/day orally for 14 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>1.31</paragraph>
                                    <paragraph>(0.43 to 3.97)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="top">
                                    <paragraph>1.3</paragraph>
                                    <paragraph>(0.69 to 2.43)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="_Ref405809172" width="100%">
                           <caption>Table 2. Drug Interactions: Pharmacokinetic Parameters for Azithromycin in the Presence of Co-administered Drugs [see <linkHtml href="#_RefID_83b2fb0a-2f21-4048-88ce-bd5cdfce9">Drug Interactions (7.3)</linkHtml>].</caption>
                           <col width="18%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="5%"/>
                           <col width="22%"/>
                           <col width="22%"/>
                           <tbody>
                              <tr>
                                 <td rowspan="2" styleCode="Rrule Botrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Co-administered Drug</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of </content>
                                       <br/>
                                       <content styleCode="bold">Co-administered Drug</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Dose of Azithromycin</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">n</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Ratio (with/without co-administered drug) of Azithromycin Pharmacokinetic Parameters (90% CI); No Effect = 1</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Mean C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Mean AUC</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Efavirenz</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>400 mg/day for 7 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>600 mg orally on day 7</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.22</paragraph>
                                    <paragraph>(1.04 to 1.42)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.92<footnote ID="_Ref405807632">- 90% Confidence interval not reported</footnote>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Fluconazole</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>200 mg orally single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1,200 mg orally single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Toprule Botrule " valign="middle">
                                    <paragraph>0.82</paragraph>
                                    <paragraph>(0.66 to 1.02)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Toprule Botrule " valign="middle">
                                    <paragraph>1.07</paragraph>
                                    <paragraph>(0.94 to 1.22)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>Nelfinavir</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>750 mg three times a day for 11 days</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>1,200 mg orally on day 9</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2.36</paragraph>
                                    <paragraph>(1.77 to 3.15)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Toprule " valign="middle">
                                    <paragraph>2.12</paragraph>
                                    <paragraph>(1.80 to 2.5)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_9a869950-5c90-4e7a-9f33-e507fe17c678">
                     <id root="b680927b-7b61-454c-ad2c-a3349aa26f2d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology </title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Mechanism of Action</content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin acts by binding to the 23S rRNA of the 50S ribosomal subunit of susceptible microorganisms inhibiting bacterial protein synthesis and impeding the assembly of the 50S ribosomal subunit.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Resistance</content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin demonstrates cross-resistance with erythromycin. The most frequently encountered mechanism of resistance to azithromycin is modification of the 23S rRNA target, most often by methylation. Ribosomal modifications can determine cross resistance to other macrolides, lincosamides and streptogramin B (MLS<sub>B</sub> phenotype). </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Antimicrobial Activity</content>
                           </content>
                        </paragraph>
                        <paragraph>Azithromycin has been shown to be active against the following microorganisms, both <content styleCode="italics">in vitro </content>and in clinical infections. [<content styleCode="italics">see <linkHtml href="#S1.3">Indications and Usage (1)</linkHtml>
                           </content>]</paragraph>
                        <paragraph>
                           <content styleCode="bold">Gram-positive Bacteria                                                     Other Bacteria </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus                                                        Chlamydophila pneumoniae</content>
                           <br/>
                           <content styleCode="italics">Streptococcus pneumoniae                                                  Chlamydia trachomatis</content>
                           <br/>
                           <content styleCode="italics">                                                                                             Mycoplasma hominis</content>
                           <br/>
                           <content styleCode="bold">Gram-negative Bacteria </content>                                                   <content styleCode="italics">Mycoplasma pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae </content>
                           <br/>
                           <content styleCode="italics">Moraxella catarrhalis </content>
                           <br/>
                           <content styleCode="italics">Neisseria gonorrhoeae </content>
                           <br/>
                           <content styleCode="italics">Legionella pneumophila </content>
                        </paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an <content styleCode="italics">in vitro</content> minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for azithromycin against isolates of similar genus or organism group. However, the efficacy of azithromycin in treating clinical infections caused by these bacteria has not been established in adequate and well-controlled clinical trials.</paragraph>
                        <table styleCode="Noautorules" width="100%">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Aerobic Gram-Positive Bacteria</content>
                                       <br/>
                                       <content styleCode="italics">Streptococci</content> (Groups C, F, G)<br/>
                                       <content styleCode="italics">Viridans</content> group <content styleCode="italics">streptococci</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Anaerobic Bacteria </content>
                                       <br/>
                                       <content styleCode="italics">Peptostreptococcus</content> species<br/>
                                       <content styleCode="italics">Prevotella bivia</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top"/>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Other Bacteria</content>
                                       <br/>
                                       <content styleCode="italics">Ureaplasma urealyticum</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top">
                                    <paragraph>
                                       <content styleCode="bold">Gram-Negative Bacteria</content>
                                       <br/>
                                       <content styleCode="italics">Bordetella pertussis</content>
                                    </paragraph>
                                 </td>
                                 <td valign="top"/>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220203"/>
                     <component>
                        <section ID="ID_c4c3f5bd-bdbd-48c6-83bb-d79877fff75d">
                           <id root="3bbe23ca-abd8-4630-8599-68bcf95e5662"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="underline">Susceptibility Testing</content>
                                 </content>
                              </paragraph>
                              <paragraph>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: <linkHtml href="https://www.fda.gov/STIC">https://www.fda.gov/STIC</linkHtml>.</paragraph>
                           </text>
                           <effectiveTime value="20220203"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_43bacfb6-5de3-41ac-90b7-988df2e7c654">
               <id root="633be77a-a161-41f6-9e14-e0a0cf731900"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220203"/>
               <component>
                  <section ID="ID_e2ab0066-2fa8-4d96-bf38-173ad403bb0c">
                     <id root="8e21ceb1-b51e-4eac-af65-3aa322fbb33e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals have not been performed to evaluate carcinogenic potential. Azithromycin has shown no mutagenic potential in standard laboratory tests: mouse lymphoma assay, human lymphocyte clastogenic assay, and mouse bone marrow clastogenic assay. In fertility studies conducted in male and female rats, oral administration of azithromycin for 64 to 66 days (males) or 15 days (females) prior to and during cohabitation resulted in decreased pregnancy rate at 20 and 30 mg/kg/day when both males and females were treated with azithromycin. This minimal effect on pregnancy rate (approximately 12% reduction compared to concurrent controls) did not become more pronounced when the dose was increased from 20 to 30 mg/kg/day (approximately 0.4 to 0.6 times the adult daily dose of 500 mg based on body surface area) and it was not observed when only one animal in the mated pair was treated. There were no effects on any other reproductive parameters and there were no effects on fertility at 10 mg/kg/day. The relevance of these findings to patients being treated with azithromycin at the doses and durations recommended in the prescribing information is uncertain.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0263c72c-2463-4a9c-becc-902ae2d5849d">
                     <id root="972178e0-e0d8-49cd-b455-e39e07c930cd"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Phospholipidosis (intracellular phospholipid accumulation) has been observed in some tissues of mice, rats and dogs given multiple oral doses of azithromycin. It has been demonstrated in numerous organ systems (e.g., eye, dorsal root ganglia, liver, gallbladder, kidney, spleen and/or pancreas) in dogs and rats treated with azithromycin at doses which, expressed on the basis of body surface area, are similar to or less than the highest recommended adult human dose. This effect has been shown to be reversible after cessation of azithromycin treatment. Based on the pharmacokinetic data, phospholipidosis has been seen in the rat (50 mg/kg/day dose) at the observed maximal plasma concentration of 1.3 mcg/mL (1.6 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g.) Similarly, it has been shown in the dog (10 mg/kg/day dose) at the observed maximal serum concentration of 1 mcg/mL (1.2 times the observed C<sub>max</sub> of 0.821 mcg/mL at the adult dose of 2 g).</paragraph>
                        <paragraph>Phospholipidosis was also observed in neonatal rats dosed for 18 days at 30 mg/kg/day, which is less than the pediatric dose of 60 mg/kg based on body surface area. It was not observed in neonatal rats treated for 10 days at 40 mg/kg/day with mean maximal serum concentrations of 1.86 mcg/mL, approximately 1.5 times the C<sub>max</sub> of 1.27 mcg/mL at the pediatric dose. Phospholipidosis has been observed in neonatal dogs (10 mg/kg/day) at maximum mean whole blood concentrations of 3.54 mcg/mL, approximately 3 times the pediatric dose C<sub>max</sub>. The significance of the findings for animals and for humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_c37dbcf8-7b6e-47cd-88a9-06b259111bad">
               <id root="e1dcfffd-60ba-4732-aaa6-8dfc060c501c"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20220203"/>
               <component>
                  <section ID="ID_cb5c8239-7288-4585-aeec-227b84cd7229">
                     <id root="f2f265cd-8341-4a2a-833b-fd1c7c17f5d0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Community-Acquired Pneumonia</title>
                     <text>
                        <paragraph>In a controlled trial of community-acquired pneumonia performed in the U.S., azithromycin (500 mg as a single daily dose by the intravenous route for 2 to 5 days, followed by 500 mg/day by the oral route to complete 7 to 10 days therapy) was compared to cefuroxime (2,250 mg/day in three divided doses by the intravenous route for 2 to 5 days followed by 1,000 mg/day in two divided doses by the oral route to complete 7 to 10 days therapy), with or without erythromycin. For the 291 patients who were evaluable for clinical efficacy, the clinical outcome rates, i.e., cure, improved, and success (cure + improved) among the 277 patients seen at 10 to 14 days post-therapy were as follows:</paragraph>
                        <table cellpadding="0pt" width="100%">
                           <col width="28%"/>
                           <col width="38%"/>
                           <col width="35%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Outcome</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Azithromycin</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Comparator</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Cure</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>46%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>44%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Improved</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>32%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>30%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Success (Cure + Improved)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>78%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="middle">
                                    <paragraph>74%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In a separate, uncontrolled clinical and microbiological trial performed in the U.S., 94 patients with community-acquired pneumonia who received azithromycin in the same regimen were evaluable for clinical efficacy. The clinical outcome rates, i.e., cure, improved and success (cure + improved) among the 84 patients seen at 10 to 14 days post-therapy were as follows:</paragraph>
                        <table cellpadding="0pt" width="100%">
                           <col width="47%"/>
                           <col width="53%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Clinical Outcome</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Azithromycin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Cure</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>60%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Improved</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>29%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>Success (Cure + Improved)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="middle">
                                    <paragraph>89%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Microbiological determinations in both trials were made at the pre-treatment visit and, where applicable, were reassessed at later visits. Serological testing was done on baseline and final visit specimens. The following combined presumptive bacteriological eradication rates were obtained from the evaluable groups:</paragraph>
                        <paragraph>Combined Bacteriological Eradication Rates for Azithromycin:</paragraph>
                        <table cellpadding="0pt" width="100%">
                           <col width="49%"/>
                           <col width="26%"/>
                           <col width="25%"/>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>a</sup>   Nineteen of twenty-four patients (79%) with positive blood cultures for <content styleCode="italics">S. pneumoniae </content>were cured (intent-to-treat analysis) with eradication of the pathogen.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">(at last completed visit)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="2" styleCode="Botrule Lrule Toprule " valign="bottom">
                                    <paragraph>
                                       <content styleCode="bold">Azithromycin</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">S. pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>64/67</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="bottom">
                                    <paragraph>(96%)<sup>a</sup>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">H. influenzae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>41/43</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="bottom">
                                    <paragraph>(95%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">M. catarrhalis</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="bottom">
                                    <paragraph>9/10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="bottom">
                                    <paragraph>(90%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">S. aureus</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="bottom">
                                    <paragraph>9/10</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="bottom">
                                    <paragraph>(90%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The presumed bacteriological outcomes at 10 to 14 days post-therapy for patients treated with azithromycin with evidence (serology and/or culture) of atypical pathogens for both trials were as follows:</paragraph>
                        <table cellpadding="0pt" width="100%">
                           <col width="29%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <col width="18%"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Botrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Evidence of Infection</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Total</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Cure</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Improved</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule Toprule " valign="middle">
                                    <paragraph>
                                       <content styleCode="bold">Cure + Improved</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Mycoplasma pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>18</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>11 (61%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>5 (28%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>16 (89%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Chlamydia pneumoniae</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>34</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>15 (44%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Lrule Botrule " valign="middle">
                                    <paragraph>13 (38%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Lrule Botrule " valign="middle">
                                    <paragraph>28 (82%)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule " valign="middle">
                                    <paragraph>
                                       <content styleCode="italics">Legionella pneumophila</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>16</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>5 (31%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule Lrule " valign="middle">
                                    <paragraph>8 (50%)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule Lrule " valign="middle">
                                    <paragraph>13 (81%)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20220203"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_a136925f-1fcb-459e-b99e-4cf558776ebd">
               <id root="7bda743e-9c18-40a2-8d6b-e0eb8cad1352"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Azithromycin for Injection, USP is supplied as white to off-white lyophilized powder in a single-dose ADD-Vantage<sup>®</sup> vial equivalent to 500 mg of azithromycin for intravenous administration.</paragraph>
                  <paragraph>These are packaged as follows:</paragraph>
                  <table width="100%">
                     <col width="50%"/>
                     <col width="50%"/>
                     <thead>
                        <tr>
                           <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <content styleCode="bold">Unit of Sale</content>
                           </th>
                           <th align="left" styleCode="Rrule Botrule Toprule " valign="middle">
                              <content styleCode="bold">Concentration</content>
                           </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr>
                           <td styleCode="Rrule Botrule Lrule Toprule " valign="middle">
                              <paragraph>
                                 <content styleCode="bold">NDC 0409-0144-11</content>
                                 <br/>Tray containing 10 single-dose ADD-Vantage<sup>®</sup> vials</paragraph>
                           </td>
                           <td styleCode="Rrule Botrule Toprule " valign="middle">
                              <paragraph>500 mg/vial</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store the lyophilized cake at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.]</paragraph>
               </text>
               <effectiveTime value="20220203"/>
            </section>
         </component>
         <component>
            <section ID="ID_aaa7e1ae-f1bb-4650-81ff-ad93863cfab1">
               <id root="370badd3-7396-4e3a-a72d-d9f7f17817ae"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Patients should be informed of the following serious and potentially serious adverse reactions that have been associated with Azithromycin for Injection:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Diarrhea: </content>Inform patients that diarrhea is a common problem caused by antibacterial drugs which usually ends when the antibacterial is discontinued. Sometimes after starting treatment with antibacterials, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibacterial. If this occurs, patients should notify their physician as soon as possible.<br/>
                  </paragraph>
                  <paragraph>Distributed by Hospira, Inc., Lake Forest, IL 60045 USA</paragraph>
                  <renderMultiMedia ID="id1421135118" referencedObject="ID_332fe979-9bff-425d-aff7-320781fcdf40"/>
                  <paragraph>LAB-1012-7.0</paragraph>
               </text>
               <effectiveTime value="20220203"/>
               <component>
                  <observationMedia ID="ID_332fe979-9bff-425d-aff7-320781fcdf40">
                     <text>Hospira logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="azithromycin-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_93162d7e-ed01-4787-b424-4cd99f498449">
               <id root="ca167fc5-2f97-4ccd-b5f9-3d9b343e2a51"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</title>
               <text>
                  <paragraph>Single-dose<br/>ADD-Vantage<sup>® </sup>Vial</paragraph>
                  <paragraph>NDC 0409-0144-21<br/>Rx only</paragraph>
                  <paragraph>Azithromycin<br/>for Injection, USP</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph> For Intravenous Use</paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>Distributed by Hospira, Inc.<br/>Lake Forest, IL 60045 USA</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id2014" referencedObject="MM1"/>
               </text>
               <effectiveTime value="20220203"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Vial Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="azithromycin-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_e9666506-1b3f-47fd-a188-19f086c6cee5">
               <id root="41542fbb-8c13-421b-8696-f41c38b93c49"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Vial Tray</title>
               <text>
                  <paragraph>10 Single-dose ADD-Vantage<sup>®</sup> Vials<br/>Rx only</paragraph>
                  <paragraph>NDC 0409-0144-11<br/>Contains 10 of NDC 0409-0144-21</paragraph>
                  <paragraph>Azithromycin<br/>for Injection, USP</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph> For Intravenous Use </paragraph>
                  <paragraph>Sterile</paragraph>
                  <paragraph>500 mg/vial</paragraph>
                  <paragraph>Hospira</paragraph>
                  <renderMultiMedia ID="id2039" referencedObject="MM2"/>
               </text>
               <effectiveTime value="20220203"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Vial Tray</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="azithromycin-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>